125 results
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical … in this prospectus supplement.
S-3
THE COMPANY
Overview
We are a biopharmaceutical company focused on the development of innovative therapeutics
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
BioPharma Group plc (the “Company” or “Mereo”) is United Kingdom (“U.K.”) based biopharmaceutical company focused on the development of innovative … -looking statements.
Overview
We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our two rare disease … infrastructure to commercialize the products in key markets.
Our Strategy
We intend to become a leading biopharmaceutical company developing innovative
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
shares of the Company.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics
8-K
EX-99.1
y6gpji68v0rnwqea
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
zs91pvu
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
6ejvb9q i19
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
6pa qceq2s13d
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
t0usm ch07eyrfjgph11
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
cg8bnak 4losmo
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
e0rtecyx3ls989 ycch
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
mmmlnz14y5khrbp1 37f
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
mk9a7ab
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
pvfcoah8yyy9vibb7
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
tu30ndm7
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
zyjo3o7g ay4
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.1
9rgbrzvon9
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
t7sgd5d2cj0eb
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
04mwoaa 4ax6a892x
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am